Enrofloxacin

Bacterial infections in livestock and poultry are common diseases in the process of livestock breeding. For a long time, there have been pain points of strong pathogenic drug resistance and high prevention and control costs. Enrofloxacin, as a special fluoroquinolone antibacterial drug for animals, blocks nucleic acid replication by inhibiting the activity of bacterial DNA gyrase, and has a strong killing effect on Gram-negative bacteria, Gram-positive bacteria and mycoplasma. It is mainly used clinically to prevent and treat respiratory, digestive and urogenital tract infections in livestock and poultry such as pigs, chickens and cattle. It is one of the core varieties in the current anti-infective drug catalog for livestock and poultry breeding, and plays an important role in standardizing breeding and reducing the risk of epidemic transmission.

The global market size of veterinary fluoroquinolone drugs has exceeded USD 1.2 billion in 2023, among which enrofloxacin accounts for approximately 11%, and the compound annual growth rate is maintained at around 4.2%. The main drivers of market growth come from the increase in the proportion of large-scale breeding worldwide and the stricter supervision on the compliant use of veterinary antibacterial drugs. In terms of the domestic market, enrofloxacin is a commonly used drug in livestock and poultry breeding and is not included in the centralized procurement scope. At present, domestic API manufacturers are mainly local manufacturers, and compliant production capacity is mainly concentrated in Shandong, Jiangsu and other regions, with a relatively stable overall supply pattern.

The original developer of enrofloxacin is Bayer AG, and the original brand name is Baytril. The core compound patent of enrofloxacin in major global markets expired around 2004. The main dosage forms of the original marketed products include injections, tablets and solutions, with common specifications such as 5% injection and 2.5% oral solution. The original preparation has been included in the FDA Reference Listed Drug Catalog. In China, at present, enrofloxacin APIs from a number of enterprises have obtained A-status registration numbers through CDE registration, and corresponding preparations such as enrofloxacin injection and enrofloxacin soluble powder have multiple domestic varieties approved for marketing. (Data as of June 2025, please refer to the official CDE website for the latest information)

In response to the needs of enrofloxacin quality research and compliance declaration, CATO provides a full set of impurity reference standards for this API. Most impurities can be supplied from stock, and in-stock products ordered before 16:00 can be shipped on the same day. All products meet the requirements of multiple regulatory systems such as the Chinese Pharmacopoeia and FDA, and can fully meet the needs of various scenarios such as quality control and registration declaration of veterinary drug manufacturers.